Formycon Reports the US FDA Acceptance of BLA for FYB203 (biosimilar, aflibercept) to Treat Retinal Diseases
Shots:
- The US FDA has accepted the BLA for FYB203 (biosimilar, aflibercept) for the treatment of severe retinal diseases. The US FDA’s decision is expected in June 2024
- Eylea is indicated for the treatment of nAMD and other severe retinal diseases that inhibit vascular endothelial growth factor for the excessive formation of blood vessels in the retina
- Additionally, six biosimilars are currently being developed by Formycon. The company is also working on the development of FYB207, based on its extensive experience in the development of biopharmaceutical drugs
Ref: FORMYCON | Image: FORMYCON
Related News:- Formycon AG and its License Partner Klinge Biopharma GmbH Report the BLA Submission of FYB203 (biosimilar, aflibercept) to the US FDA
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
